glp-1 obesity drug news today september 29 2025 Weight-loss makers announce pricing agreement with Trump Lilly hikes revenue forecasts on

If you are among them, one...

In stock: Ships free in 1-4 days, if prescribed Medication shipped directly to your door

Crafted for those serious about appetite control, glucose optimization, and metabolic health

Zealand Pharma's agreement with Roche to jointly develop and commercialise an experimental amylin-based weight-loss treatment will create a strong obesity trea

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for the treatment of type 2 diabetes and obesity, may modulate pathways associated with the hallmarks of aging

When patients on GLP-1 therapy also make healthy lifestyle choicesgetting enough sleep and exercising, for examplethe benefits are significantly greater.